Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences

Rhea-AI Summary

Vistagen Therapeutics, Inc. (Nasdaq: VTGN) announced that CEO Shawn Singh will participate in two upcoming investor conferences in New York. The events are:

• Morgan Stanley 20th Annual Global Healthcare Conference: September 13 at 9:10 a.m. ET
• Baird 2022 Global Healthcare Conference: September 14 at 2:35 p.m. ET

Vistagen is focused on transforming treatments for anxiety and depression using innovative pherines, which are designed to have rapid effects with minimal side effects.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that Chief Executive Officer, Shawn Singh, will participate in the following upcoming investor conferences in New York. Management will be available for one-on-one meetings during these conferences.

Morgan Stanley 20^th Annual Global Healthcare Conference

Format: Fireside Chat
Date and Time: Tuesday, September 13^th at 9:10 a.m. Eastern Time
Location: New York, New York
Webcast will be accessible through the Events page in the Investors section of the Company’s website at www.Vistagen.com.

Baird 2022 Global Healthcare Conference

Format: Fireside Chat
Date and Time: Wednesday, September 14^th at 2:35 p.m. Eastern Time
Location: New York, New York

About Vistagen

Vistagen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. Vistagen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherines, which are odorless and tasteless investigational neuroactive steroids designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic uptake or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. Connect at www.Vistagen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005140/en/

Investors:

Mark Flather

Vice President, Investor Relations

(650) 577-3617

mflather@vistagen.com

Media:

Nate Hitchings

SKDK

nhitchings@skdknick.com

Source: Vistagen Therapeutics, Inc.

FAQ

What is Vistagen Therapeutics, Inc. doing at the investor conferences in New York?

Vistagen Therapeutics, Inc. CEO Shawn Singh will participate in two investor conferences in New York, including the Morgan Stanley 20th Annual Global Healthcare Conference on September 13 and the Baird 2022 Global Healthcare Conference on September 14.

When are the Vistagen investor conferences scheduled?

The Morgan Stanley conference is on September 13, 2022, at 9:10 a.m. ET, and the Baird conference is on September 14, 2022, at 2:35 p.m. ET.

What is the main focus of Vistagen's therapeutics?

Vistagen Therapeutics focuses on transforming treatments for anxiety and depression, developing pherines that act rapidly with fewer side effects compared to existing options.

How can I access the Morgan Stanley conference webcast?

The Morgan Stanley conference webcast can be accessed through the Events page in the Investors section of Vistagen's website at www.Vistagen.com.

What is the stock symbol for Vistagen Therapeutics?

The stock symbol for Vistagen Therapeutics is VTGN.